Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) COO Margaret Horn sold 3,575 shares of the firm’s stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $156.12, for a total transaction of $558,129.00. Following the transaction, the chief operating officer directly owned 154,647 shares in the company, valued at approximately $24,143,489.64. The trade was a 2.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Revolution Medicines Stock Performance
Shares of NASDAQ:RVMD traded up $1.19 during trading on Wednesday, reaching $157.77. The stock had a trading volume of 2,227,327 shares, compared to its average volume of 2,761,698. Revolution Medicines, Inc. has a 52 week low of $34.00 and a 52 week high of $166.50. The firm has a market capitalization of $33.54 billion, a price-to-earnings ratio of -22.32 and a beta of 1.40. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.19. The stock has a fifty day simple moving average of $144.38 and a two-hundred day simple moving average of $112.39.
Revolution Medicines (NASDAQ:RVMD – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($2.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.46). During the same quarter in the prior year, the company earned ($1.13) EPS. As a group, analysts anticipate that Revolution Medicines, Inc. will post -7.94 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Revolution Medicines
Analyst Ratings Changes
RVMD has been the topic of a number of recent analyst reports. Oppenheimer lifted their price target on shares of Revolution Medicines from $165.00 to $195.00 and gave the company an “outperform” rating in a research report on Monday, June 1st. Sanford C. Bernstein started coverage on shares of Revolution Medicines in a research note on Thursday, May 21st. They issued a “market perform” rating and a $151.00 price objective on the stock. Guggenheim raised their price objective on shares of Revolution Medicines to $205.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Benchmark restated an “overweight” rating on shares of Revolution Medicines in a research note on Tuesday, February 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a research note on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $123.72.
View Our Latest Stock Report on Revolution Medicines
About Revolution Medicines
Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.
The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.
Read More
- Five stocks we like better than Revolution Medicines
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
